IL17A and hepatocellular carcinoma: In HCC patients with complete or partial tumor response to TACE, the levels of circulating Th1, Th17 and CD4+/IFN-γ+/IL-17+T cells increased (16), suggesting that Th17 is closely related to liver cancer, and may have the “dual identity” of tumor-promoting and anti-tumor effects at the same time (17).